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A B S T R A C T
The α7 nicotinic acetylcholine receptor has been extensively researched as a target for treatment of cognitive
impairment in Alzheimer's disease and schizophrenia. Investigation of the α7 receptor is commonly performed in
animals but it is critical to increase the biologically relevance of the model systems to fully capture the phy-
siological role of the α7 receptor in humans. For example most humans, in contrast to animals, express the
hybrid gene CHRFAM7A, the product of which modulates α7 receptor activity. In the present study, we used
human induced pluripotent stem cell (hiPSC) derived neurons to establish a humanized α7 model. We estab-
lished a cryobank of neural stem cells (NSCs) that could reproducibly be matured into neurons expressing
neuronal markers and CHRNA7 and CHRFAM7A. The neurons responded to NMDA, GABA, and acetylcholine
and exhibited synchronized spontaneous calcium oscillations. Gene expression studies and application of a range
of α7 positive allosteric modulators (PNU-120595, TQS, JNJ-39393406 and AF58801) together with the α7
agonist PNU-282987 during measurement of intracellular calcium levels demonstrated the presence of func-
tional α7 receptors in matured hiPSC-derived neuronal cultures. Pharmacological α7 activation also resulted in
intracellular signaling as measured by ERK 1/2 phosphorylation and c-Fos protein expression. Moreover, PNU-
120596 increased the frequency of the spontaneous calcium oscillations demonstrating implication of α7 re-
ceptors in human synaptic networks activity. Overall, we show that hiPSC derived neurons are an advanced in
vitro model for studying human α7 receptor pharmacology and the involvement of this receptor in cellular
processes as intracellular signaling and synaptic transmission.
1. Introduction
Development of pharmaceuticals for treatment of neurological dis-
eases e.g. Alzheimer's disease and schizophrenia, is a challenging task
due to the complexity of the diseases, lack of translational in vivo and in
vitro models, and limited access to human brain material
(Dragunow, 2008; Kesselheim et al., 2015; Selkoe, 2011). Cognitive
impairments in form of reduced attention, learning, and working
memory are frequent symptoms in both diseases. Investigations in
Alzheimer's disease models have shown several dysfunctional receptor
systems aﬀecting the basal forebrain, pre-frontal cortex, and hippo-
campus (reviewed in Millan et al., 2012). The α7 nicotinic acetylcho-
line (α7) receptor, an ionotropic receptor channel highly permeable to
calcium and enriched in areas of the hippocampus and cortex
(Breese et al., 1997; Court et al., 1997; Freedman et al., 1993), has been
broadly studied as a potential drug target for treatment of cognitive
dysfunction in Alzheimer's disease and schizophrenia (Hashimoto et al.,
2008; Haydar and Dunlop, 2010; Levin et al., 2006, 2002;
Toyohara and Hashimoto, 2010). α7 receptor function can be modu-
lated by partial agonists (Biton et al., 2007; Lieberman et al., 2013;
Prickaerts et al., 2012) as well as positive allosteric modulators (PAMs)
(Eskildsen et al., 2014; Hurst et al., 2005; Krause et al., 1998;
Timmermann et al., 2007). PAMs are compounds that bind to the re-
ceptor at sites distinct from the orthosteric site and enhance the acti-
vation amplitude (type I and II) or diminish desensitization (type II),
but show no agonist activity themselves (Grønlien et al., 2007). Indeed,
α7 PAMs have shown to improve memory and cognitive function in
vivo and are considered cognitive enhancers (Thomsen et al., 2010a;
Timmermann et al., 2007; Williams et al., 2011).
Studies in adult rat hippocampus have demonstrated the presence of
both pre- and post-synaptic α7 receptors (Fabian-Fine et al., 2001). Pre-
synaptic receptor activation promotes local depolarization, which
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enhances the probability of neurotransmitter release into the synapses
and thereby signal conductance to adjacent neurons (Thomsen et al.,
2010a). In line, presynaptic α7 receptors has been reported to modulate
both GABA (Alkondon et al., 2000; Alkondon and Albuquerque, 2001)
and glutamate (Cheng and Yakel, 2014; Gray et al., 1996; Sharma et al.,
2008) synaptic transmission in the hippocampus. Activation of post-
synaptic α7 receptors initiate downstream pathways including phos-
phorylation of the MAP kinase ERK (Dajas-Bailador et al., 2002b;
Dineley et al., 2001; El Kouhen et al., 2009) and expression of proto-
onco gene c-Fos protein (Hansen et al., 2007; Thomsen et al., 2010a,
2010b). Noticeably, embryonic α7 subunit expression is increased
compared to the adult stage (Adams et al., 2002; Falk et al., 2003),
suggesting also a developmental role of the receptor in neuronal pro-
liferation and synapse establishment (Court et al., 1997).
The discovery of human induced pluripotent stem cells (hiPSCs) was
a hallmark in modern biology oﬀering the ability to derive a whole
range of somatic cell types (Takahashi et al., 2007; Yu et al., 2007).
Importantly, this also provided a renewable source of human neurons,
which facilitated humanized in vitro modelling of neurodegenerative
and psychiatric diseases such as sporadic and familial Alzheimer's dis-
ease (Israel et al., 2012; Muratore et al., 2014) and schizophrenia
(Brennand et al., 2011). hiPSC-derived neurons provide a promising
alternative to immortalized cell lines and non-human primary neuronal
cultures for studying the α7 receptor in a human neuronal cellular
background with native genome and proteome. For example, most
humans have one or two copies of the CHRFAM7A gene consisting of a
partial duplication of the α7 gene (CHRNA7) fused to a copy of the
FAM7A gene. This gene combination is only expressed in humans and
CHRFAM7A expression reduces ACh evoked α7 currents (Araud et al.,
2011). Moreover, α7 receptor activation increases intracellular calcium
inﬂux though the α7 receptor channel, but also by secondary down-
stream eﬀects such as inﬂux via L-type voltage-gated calcium channels
and from IP3 and ryanodine receptor guarded intracellular stores
(Dajas-Bailador et al., 2002a; Guerra-Álvarez et al., 2015). Such inter-
actions with other cellular mechanisms must be better reﬂected using
neuronal models with endogenously expressed α7 receptor.
Upon neural diﬀerentiation, hiPSC-derived neurons express α7 re-
ceptors, develop synaptic connections and display spontaneous action
potentials and calcium oscillations (Gill et al., 2013; Hansen et al.,
2016; Israel et al., 2012; Muratore et al., 2014). In this study, we link
the α7 receptor expression in hiPSC-derived neurons to relevant cel-
lular processes as intracellular signaling and synaptic transmission by
(1) characterizing the native expression of the α7 receptor complex in
hiPSC-derived neurons, (2) addressing if α7 stimulation result in acti-
vation of relevant cellular downstream processes, (3) characterizing the
hiPSC-derived neurons as a model for synaptic transmission, and ﬁnally
(4) investigating the involvement of the α7 receptor in synaptic trans-
mission. The overall aims were to develop a model for studying A) α7
receptor pharmacology in a human context and B) the role of α7 re-
ceptors in cellular processes as intracellular signaling and synaptic
networks activity.
2. Materials and methods
2.1. Compounds
AF58801 (Eskildsen et al., 2014), Cx516, diazepam, and PNU-
282987 were synthesized at H. Lundbeck A/S at chemical grade with a
purity of >90%. 4-AP (275875), Acetylcholine (A6625), atropine
(A0257), ifenprodil (I2892), ketamine (K2753), mecamylamine
(M9020), MK-801 (M107), nicotine (N5260), and PNU-120596 (P0043)
were purchased from Sigma-Aldrich (Brøndby, Denmark). TQS was
synthesized by Chembridge Corporation (San Diego, CA, USA) and JNJ-
39393406 by WuXi (Shanghai, China). 2-APB (1224), bicuculline
(2503), methyllycaconitine (1029), QNZ46 (4801), ryanodine (1329),
TCN237 (4072), and tetrodotoxin citrate (1069) were purchased from
Tocris bioscience (Bristol, UK). ω-Conotoxin GVIA (H-6615) and MVIIA
(H-8210) were purchased from Bachem (Bubendorf, Switzerland).
Single doses where picked based on typical concentrations used in other
cell-based studies (in-house experience and literature data).
2.2. hiPSC generation, NSC diﬀerentiation, and NSC banking
Three hiPSCs clones (NHDF K1_shp53, K2_shp53, and K3_shp53
deposited in the European Bank of induced Pluripotent Stem Cells
(EBiSC) as BIONi010-A, BIONi010-B and BIONi010-C) from a healthy
18y male were generated and diﬀerentiated into neural stem cells
(NSCs) and master cryostocks were frozen at passage 2 (day 16–19) as
previously described (Hansen et al., 2016; Rasmussen et al., 2014).
Master cryostocks were thawed and cultured for two passages (10 days)
for establishment of a working cryobank. During generation of the
working cryobank, the NSCs were cultured in neural expansion medium
(NEM) consisting of 50% Advanced DMEM/F-12 (Thermo Fisher Sci-
entiﬁc, 12634), 50% Neurobasal medium (Thermo Fisher Scientiﬁc,
21103–049), 2% Neuronal induction supplement (Thermo Fisher Sci-
entiﬁc, A16477- 01), and 0.1% PenStrep (Thermo Fisher Scientiﬁc,
15140–122) on plates coated with 10 μg/cm2 poly- L-ornithine (Sigma-
Aldrich, P3655) and 1 μg/cm2 laminin (Sigma-Aldrich, L2020) referred
to as PLO/lam-coating at 37 °C (5% CO2, 95% humidity).
2.3. NSCs and maturation
The NSC maturation protocol is illustrated in Fig. 1A. NSC working
cryostocks (passage 4) were thawed and expanded in NEM for two days
in PLO/lam-coated 6-well plates. NSCs were split (deﬁned as day 0)
using 10min accutase (Thermo Fisher Scientiﬁc, A11105) treatment
and plated at a density of 1.6E6 cells/6-well and matured in neural
maturation medium (NMM) consisting of 50% DMEM-F12 (Thermo
Fisher Scientiﬁc, 31331–028), 50% Neurobasal medium (Thermo Fisher
Scientiﬁc, 21103–049), 0.5% N2 (Thermo Fisher Scientiﬁc,
17502–048), 0.5% B27 (Thermo Fisher Scientiﬁc, 17504–044), 0.5 mM
GlutaMAX supplement (Thermo Fisher Scientiﬁc, 35050–061), 0.5%
NEAA supplement (Thermo Fisher Scientiﬁc, 11140–050), 50 μM 2-
mercaptoethanol (Thermo Fisher Scientiﬁc, 21985023), 2.5 μg/mL in-
sulin (Sigma-Aldrich, 19278) supplemented with maturation factors:
20 ng/mL BDNF (R&D Systems, 248-BD), 10 ng/mL GDNF (R&D Sys-
tems, 212-GD), 200 μM L-Ascorbic Acid (Sigma-Aldrich, A5960), and
500 μM db-cAMP (Sigma-Aldrich, D0627). After 8/9 days in NMM, the
cells were seeded in 96-well plates at a density of 50,000 cells/well
(166,700 cells/cm2) and further matured in NMM medium for 2–5
weeks. Medium containing maturation factors was used within a week
and changed every second day. 10 μM ROCK inhibitor (Sigma-Aldrich,
Y0503) was added overnight upon thawing and splitting. The ages of
the hiPSC neurons used in the diﬀerent experiments are given as days or
weeks of culturing in NMM.
2.4. Immunocytochemistry
Cells seeded in PLO/lam-coated Cell Carrier (Perkin Elmar,
6005550) plates were ﬁxed in 4% paraformaldehyde for 15min at room
temperature, blocked in KPBS (10mM phosphate buﬀer, 150mM NaCl,
and 3.4 mM KCl) supplemented with 0.5% BSA, 0.1% triton X-100, and
5% normal swine serum (Jackson ImmunoResearch, 014–000–121) for
20min and incubated in blocking buﬀer containing primary antibody
overnight (4 °C) (listed in Supplementary). Subsequently, the samples
were incubated with secondary antibodies (listed in Supplementary)
and 0.67 ug/mL Hoechst 33342 (Invitrogen, H1399) for 1 h at room
temperature, mounted in Prolong Gold Antifade Mountant (Thermo
Scientiﬁc, P36934), and visualized on Leica DM5500 B (Leica, DE).
H.M. Larsen, et al. Stem Cell Research 41 (2019) 101642
2
2.5. Quantitative real time PCR (qPCR)
SYBR Green Cell-to-CT kit (Ambion, 4402957) was used for RNA
isolation and reverse transcription to cDNA. 4x diluted cDNA was used
as template for qPCR with TaqMan® Fast Advanced Master Mix and
TaqMan primers purchased from Thermo Scientiﬁc (listed in
Supplementary). The ΔΔ-CT method was applied to expression data and
individual genes normalized to geometric mean of housekeeping genes
(RPL13A, GUSB, and HSP90AB1), and mean of undiﬀerentiated hiPSC
cDNA samples from all three lines.
2.6. Intracellular calcium measurements
Neurons were loaded for 1 h at room temperature with Calcium-4
dye (Molecular Devices, R8141) dissolved in assay buﬀer (HBSS w/o
Ca2+/Mg2+, 20mM HEPES (Sigma-Aldrich, H4034), 3 mM CaCl).
Image based measurement of cytosolic calcium kinetics (excitation and
emission wavelengths of 480, and 540 nm, respectively) and compound
applications were conducted using the FDSS7000 system (Hamamatsu,
Japan). The instrument readout is the total ﬂuorescent intensity per
well in relative ﬂuorescence units (RFU), which are reported as ratio to
the ﬁrst sampling data point and termed “RFU ratio” throughout the
manuscript. Dimethyl sulfoxide (DMSO) assay concentration was
maintained at ≤0.5% and kept constant within diﬀerent conditions of
the same experiments. The FDSS application paradigm used in
experiments shown in Figs. 2D, 2E, 2F, 2G, 3A and 3B is illustrated in
Fig. 2C, except that in Fig. 2G a 30min preincubation with inhibitor
was included in the experiment. 25mM KCl application was included in
a set of wells on all plates as plate to plate calibrator. Experiments were
performed at room temperature. FDSS7000Ex/uCell software was used
to quantify the maximum RFU ratio upon agonist application, where
after vehicle values were subtracted and data were normalized to the
mean maximum ratio upon KCl stimuli. The Data in Fig. 2G was ad-
ditionally normalized to the response to PNU282987+PNU120596 in
the absence of inhibitor. Calcium oscillations recordings were per-
formed at 37 °C. FDSS data shown in Fig. 4 were done as 20min mea-
surement of spontaneous calcium oscillations (baseline activity) and
20min measurements in the presences of pharmacological treatments.
The number of peaks and the mean peak amplitudes in the 20min in-
tervals were quantiﬁed using FDSS7000Ex/uCell combined with FDSS
Waveform Analysis software. Data from individual wells were nor-
malized to their baseline values (as well-to-well normalizer) and to
mean of vehicle control.
2.7. Western blotting
Neurons were washed, and assay buﬀer added 3 h prior to stimu-
lation. Stimulation compounds were diluted in assay buﬀer. For phos-
phorylation of ERK neurons were incubated for 5min (37 °C) and for c-
Fos 1 h (37 °C). Neurons were harvested in DPBS (w/o Mg2+/Ca2+)
Fig. 1. Maturation of hiPSC-derived
NSCs to spontaneously active neurons.
A: NSC maturation protocol used for
diﬀerentiation of spontaneously active
neurons. Protocol is depicted with time
points, medium, and supplements. B: q-
PCR for gene expression of plur-
ipotency marker Oct-4 (POU5F1,
P<0.0001 day 14–35 compared to day
0), neuronal markers βIII-tubulin
(TUBB3, P<0.05 day 14–21, P<0.001
day 28 and P<0.0001 day 35 com-
pared to day 0) and microtubule asso-
ciated protein-2 (MAP2, P<0.05 day
14, P<0.001 day 21 and P<0.0001
day 28–35 compared to day 0), and
post-mitotic neuron marker NeuN
(RBFOX2, P<0.01 day 21 and
P<0.001 day 28–35 compared to day
0) at diﬀerent stages of diﬀerentiation
(mean± SEM, n=3, m=4). C:
Immunocytochemistry of the hiPSC-
derived neurons showing protein ex-
pression of neuroprogenitor markers
nestin and vimentin, cell proliferation
marker Ki67, neuronal markers dou-
blecortin, βIII-tubulin (TuJ1), MAP2,
and Tau, and NeuN. Scale bars: 100 μm
(d21, n=3, m=1, exempliﬁed with
BIONi010A) D: Changes in in-
tracellular calcium following applica-
tion of 100 μM GABA, 100 μM dopa-
mine (DA), 300 μM acetylcholine
(ACh), 300 μM glutamate (Glu;
+10 μM glycin), 100 μM serotonin (5-
HT), 25mM potassium chloride (K+)
(mean for each n, d21-22, n=3,
m=4). E: Eﬀect of 250 μM 4-AP fol-
lowed by 1 μM TTX on neuronal cal-
cium oscillations (representative traces
are shown for each line, d28, n=3,
m=4).
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containing protease and phosphatase inhibitor cocktail (Roche,
11697498001, 04906837001), centrifuged (1000xg, 10min, 4 °C), and
lysed for 30min in RIPA buﬀer (Sigma-Aldrich, R0278) supplemented
with inhibitor cocktail. Lysate was centrifuged (18.000xg, 20min, 4 °C),
and the supernatant was collected and stored at −80 °C. Protein con-
centration was determined using Pierce BCA (Thermo Scientiﬁc,
23,225). Samples were mixed with loading buﬀer to a ﬁnal con-
centration of 100mM DDT, 1x NuPAGE LDS sample buﬀer (Thermo
Scientiﬁc, NP0007) and incubated at 95 °C for 5min. 10 μg protein was
loaded in 15 wells NuPAGE Novex 4–12% Bis-Tris protein gels (Thermo
Scientiﬁc, NP0323) with Chameleon Duo protein ladder (LI-COR,
928–6000). Electrophoresis was done at 200 V with variable power and
electrical current for 45min on ice. Gel was blotted to nitrocellulose
membrane (Thermo Scientiﬁc, IB23001) using iBlot 2 dry blotting
(Thermo Scientiﬁc, IB21001). Nitrocellulose membrane was blocked in
blocking buﬀer (1:1 LI-COR, 927–40,000 and DPBS) for 30min with
shaking. Primary antibodies (listed in Supplementary) were diluted in
blocking buﬀer and incubated overnight at 4 °C on a rotating table.
Following 6 washes (30min) in DPBS+0.1% tween, membranes were
incubated with secondary antibodies diluted in secondary buﬀer (DPBS,
Fig. 2. hiPSC-derived neurons express
functional α7 receptors.
A: q-PCR for gene expression of nAChR
subunits α7 (CHRNA7, P<0.01 week
3–4 and P<0.001 week 5 compared to
day 0), α4 (CHRNA4, P<0.01 week
3+ 5 and P<0.001 week 4 compared
to day 0), β2 (CHRNB2, P<0.05 day 14
and P<0.0001 week 3–5 compared to
day 0), hybrid α7 (CHRFAM7A,
P<0.05 week 3, P<0.001 week 4 and
P<0.0001 week 5 compared to day 0),
and chaperone transmembrane protein
35A (TMEM35, P<0.01 week 3,
P<0.0001 week 4 and P<0.001 week
5 compared to day 0) at diﬀerent stages
of neuronal diﬀerentiation
(mean± SEM, n=3, m=4). B:
Western blot of TMEM35 in d21 hiPSC-
derived neurons, PC12 cells, mouse
cerebrum (mCC), and cerebellum
(mCE) (n=1, m=1). C: Compound
application paradigm used in 2D, 2E,
2F, 2 G. D: Calcium traces showing α7
stimulation (3 μM PNU-120596 plus
10 μM PNU-282987) in the presence or
absence of 1 μM TTX. Arrows indicate
additions outlined in “C” (mean, n=3,
m=4). E: Change in intracellular cal-
cium following stimulation with
100 μM acetylcholine (ACh), 25 μM ni-
cotine, and 10 μM PNU-282987 alone
or in the presence of 3 μM PNU-
120596, 1 μM MLA or 10 μM DhβE
(mean± SEM, d21-22, n=3,
n=2–4). The experiments were done
in the presence of TTX. F:
Concentration-dependent activation of
α7 with ACh and PNU-282987 in the
presence and absence of 3 μM PNU-
120596, and concentration-dependent
inhibition of α7 with antagonist MLA
(mean± SEM, d21, n=3, n=4). The
experiments were done in the presence
of TTX. G: Eﬀects of inhibiting voltage-
gated channels or calcium release from
intracellular calcium stores on α7
evoked cytosolic calcium. Neural cul-
tures were pre-incubated with channel
blockers (1 μM nifedipine, 1 μM w-CTx
GVIA, 1 μM w-CTx MVIIA, or 1 μM
TTX) or blockers of calcium release
from intracellular calcium stores
(10–30 μM 2-APB, or 10–30 μM ryano-
dine) 30min prior to α7 stimulation
with 3 μM PNU120596 and 10 μM PNU-282987 (mean± SEM, d20-23, n=3, m=4). The experiments were done in the presence of TTX H: Western blot of pERK/
ERK (sum of pERK and ERK1/2) and c-Fos following α7 stimulation with indicated compounds (mean± SEM, d23-26, n=3, n=2). Representative blots are shown
below graphs. All ﬁgure panels: Statistical signiﬁcance was determined using one-way ANOVA followed by post hoc Dunnett's or Sidak's multiple comparison test;
*P<0.05, **P<0.01, ***P<0.005.
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0.1% tween, 0.02% SDS) for 1 h, washed 6 times in DPBS+0.1% tween,
and 2 times in PBS, and scanned on LI-COR Odyssey CLx. Data were
extracted using Imaging Studio (LI-COR, 9140–500).
2.8. Curve ﬁtting and statistical analysis
All data analyses were conducted in Excel (Microsoft, CA). Curve
ﬁtting and statistical analysis were done using Prism (GraphPad, La
Jolla). All data are shown as mean± SEM (“n”= individual cell lines
run in independent experiments except in Fig. 2D where the lines were
run in parallel, “m”=technical replicates) unless stated otherwise.
3. Results
3.1. hiPSC-derived neurons express neuronal markers, respond to
neurotransmitters and show synchronized calcium oscillations
We aimed at generating a reproducible hiPSC-based system for in-
vestigating natively expressed functional α7 receptors in a system with
a good throughput. From a single working stock cryovial (4× 106
NSCs), we generate 22×106± 1×106 NSCs, i.e. enough for seeding
three to four 96-well plates (50.000 cells/well). To account for the
variance induced by ﬁbroblast reprogramming or cell culture related
factors, experiments were conducted with three hiPSC clones. We used
qPCR to determine gene expression relative to undiﬀerentiated hiPSCs,
at four time points during terminal maturation of the NSCs into neurons
(day 14, 21, 28, 35/36). Onset of diﬀerentiation was associated with a
down-regulation of the pluripotency marker OCT4 (POU5F1) and an
upregulation of the pan-neuronal markers, βIII-tubulin (TUBB3, 60-
folds day 35), microtubule associated protein-2 (MAP2, 200-folds day
35/36) and NeuN (RBFOX2, 29-folds day 35/36), which all three had
reached a plateau from week 3 (Fig. 1B). Immunostainings at day 21
(Fig. 1C) conﬁrmed the presence of MAP2, βIII-tubulin, and NeuN
protein and additionally showed expression of doublecortin and mi-
crotubule associated protein tau. Smaller subpopulations were positive
for the neuronal progenitor markers (nestin, vimentin) and the pro-
liferation marker Ki67.
Based on the pan-neuronal mRNA and protein marker expression in
our neuronal cultures, we hypothesized that the cultures would be
suﬃciently mature to express several receptor classes. To address this,
we investigated the eﬀects of neurotransmitters on intracellular calcium
levels (Fig. 1D). The experiments were performed in the presence of
tetrodotoxin (TTX, 1 μM) to eliminate spontaneous calcium oscillations
blurring the neurotransmitter responses. Intracellular calcium increased
in response to the neurotransmitters γ-aminobutyric acid (GABA,
100 μM), acetylcholine (300 μM), and glutamate (300 μM). Further-
more, depolarization of the membrane potential by addition of po-
tassium chloride increased intracellular calcium levels, most likely by
opening of voltage-gated calcium channels. Neither dopamine nor ser-
otonin had any eﬀect on calcium levels. The calcium assay only reveals
the presence of a receptor if its activation causes a calcium inﬂux. It
may be directly via the receptor or via downstream eﬀects. Hence, the
presence of dopamine and serotonin receptors cannot be excluded, even
though they were not demonstrated. G protein–coupled GABAB re-
ceptors are linked to inactivation, and not activation, of voltage-gated
calcium channels (Chalifoux and Carter, 2011). Therefore, the GABA
eﬀect probably reﬂects activation of GABAA, chloride channels, re-
sulting in membrane depolarization and secondary opening of voltage-
gated calcium channels. In the adult brain, GABA is an inhibitory
neurotransmitter. In the immature brain, high intracellular chloride
concentrations are reported to result in depolarizing GABA responses in
neurons (Succol et al., 2012). However, as the Nernst equilibrium po-
tential for chloride is close to typical neuronal membrane potentials,
experimental conditions will be highly determining for whether GABAA
receptor activation induces depolarization or hyperpolarization. Whe-
ther one or the other reason explains the GABA induced calcium in-
crease in our cultures, the data demonstrate the presence of functional
GABA receptors.
Neurons from all three hiPSC clones showed the same response
pattern.
In some experiments, spontaneous calcium oscillations were ob-
served as early as week 3. Keeping the neurons in culture for one ad-
ditional week resulted in consistent presence of spontaneous calcium
oscillations. Coordinated synchronized network activity is required to
detect oscillations in the applied calcium assay, as the readout is the
total ﬂuorescence per wells. Hence the data demonstrate synaptic
connectivity in the cultures. This was further conﬁrmed by live imaging
(see Fig. S1). Application of the voltage-gated potassium channel
blocker 4-aminopyridine (4-AP, 250 μM) resulted in an increase in os-
cillation amplitude and frequency (Fig. 1E), presumable by easing
membrane potential depolarization. Addition of the voltage-gated so-
dium channel blocker TTX (1 μM) abolished all activity (Fig. 1E) ver-
ifying a role for action potentials in facilitation of the coordinated
calcium oscillations.
3.2. hiPSC-derived neurons express functional α7 receptors
We used qPCR to examine the changes in gene expression of nico-
tinic acetylcholine receptor (nAChR) subunits during neuronal ma-
turation (Fig. 2A). α4 (CHRNA4) showed the largest upregulation (45-
folds day 35), while β2 (CHRNB2) (12-folds day 35), and α7 (CHRNA7)
(5-folds day 35) expression changes were more limited. Interestingly,
also the human speciﬁc hybrid α7 gene (CHRFAM7A) was up-regulated
(20-folds day 35). The gene product is reported to co-assembles with
native α7 subunits and act as a dominant negative modulator of the
receptor function (Sinkus et al., 2015). This highlights the importance
of using a human α7 model. We also investigated the expression of
chaperone TMEM35, recently shown to be required for surface ex-
pression of the α7 receptor complex (Gu et al., 2016). TMEM35 mRNA
expression was up-regulated (44-folds day 35), and interestingly cor-
related with CHRNA4 and CHRNB2 expression levels (Fig. 2A).
TMEM35 protein expression was conﬁrmed by Western Blotting
(Fig. 2B).
We addressed the expression of functional α7 receptors by
Fig. 3. Chemically diverse α7 positive allos-
teric modulators show concentration-depen-
dent activation of α7.
A/B: Concentration-response of α7 positive
allosteric modulators (type 2: PNU-120596
(PNU12), TQS, type 1/2: AF58801 (AF58),
JNJ-39393406 (JNJ-29)) and α7 receptor an-
tagonist MLA following stimulation with 10 μM
PNU- 282987 according to the paradigm
shown in Fig. 2C (mean± SEM, d21-22, n=3,
m=4). Experiments were done in the presence
of TTX.
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pharmacological characterization using the compound application
paradigm described in Fig. 2C and assessing eﬀects on intracellular
calcium. Calcium levels increased in response to stimuli with α7 re-
ceptors type II PAM, PNU-120596 (3 μM) (Hurst et al., 2005) when
combined with the selective α7 agonist, PNU-282987 (10 μM)
(Hajós et al., 2005) (Fig. 2D). This was evident at all neuronal ma-
turation timepoints, i.e. indicating functional receptor expression at
week 2, 3 and 4. At week 3–4, concurrent application of TTX reduced
the α7-induced calcium signal. This implies ampliﬁcation of the cal-
cium response by secondary eﬀects dependent on voltage-gated sodium
(caption on next page)
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channel activation.
Intracellular calcium measurements functionally conﬁrmed the
nAChR subunits heterogeneity indicated by the qPCR data:
Acetylcholine (100 µM) and nicotine (25 μM) treatments induced small
increases in intracellular calcium levels, which were strongly ampliﬁed
by PNU-120596 (3 μM). PNU-282987 (10 μM) alone had no eﬀect, but
the signal strongly increased with co-application of PNU-120596
(Fig. 2E). The α7 antagonist, methyllycaconitine (MLA, 1 μM)
(Briggs et al., 1995; Macallan et al., 1988) strongly reduced acet-
ylcholine and nicotine signals, while it abolished the PNU-282987
signal (Fig. 2E). The α4β2 antagonist DhβE (1 μM) did not signiﬁcantly
reduce the signal of acetylcholine and nicotine (Fig. 2E). Overall, the
pharmacological responses demonstrated nAChR subunits hetero-
geneity and the presence of functional α7 receptors. To substantiate the
pharmacological demonstration of α7 in the hiPSC-derived neuronal
cultures, we showed that acetylcholine and PNU-282987 in combina-
tion with PNU-120596 (3 μM) resulted in a concentration-dependent
increase in intracellular calcium with EC50s of 3 μM and 34 nM, re-
spectively (Fig. 2F). Likewise, a concentration-dependent inhibition
was observed with increasing concentrations of MLA (Fig. 2F). Full
inhibition of the α7 signal was achieved with 1 μM MLA.
We challenged the system with voltage-gated sodium and calcium
channel blockers and inhibitors of intracellular calcium stores to
identify the secondary mechanisms of intracellular calcium increase
upon α7 receptor activation (Fig. 2 G). Application of TTX (1 μM) and
the L-type voltage-gated calcium channel blocker nifedipine (1 μM) re-
duced the α7 peak amplitude, while no or very minor eﬀects were seen
of N-type voltage-gated calcium channel blockers ω-Conotoxin GVIA
(1 μM) and ω-Conotoxin MVIIA (1 μM). The ryanodine receptor in-
hibitor ryanodine caused a border line (P<0.05 with 10 µM) reduction
of the α7 peak amplitude, while the inositol trisphosphate receptor
inhibitor (IP3), 2-aminoethoxydiphenylborate (2-APB) signiﬁcantly
(P<0.0001) decreased the amplitude in both concentrations tested.
This demonstrates inﬂux of extracellular calcium via L-type voltage-
gated calcium channel as well as release from intracellular stores.
Stimulating the hiPSC-derived neurons with PNU-120596 (10 μM)
combined with PNU- 282987 (10 μM) resulted in increased ERK 1/2
phosphorylation and c-Fos protein expression (P<0.05) (Fig. 2H). As
expected, MLA (1 μM) had an antagonizing eﬀect. In line with the data
of Fig. 2E, PAM was needed to introduce an eﬀect in these downstream
pathways. The ERK 1/2 phosphorylation and c-Fos data reveal that α7
receptor stimulation activates intracellular signaling.
3.3. α7 activation was achieved by type II and intermediate type I/II positive
allosteric modulators
Using the paradigm shown in Fig. 2C, we applied a selection of
chemically diverse α7 PAMs in combination with PNU-282987. Both
type-II PAMs (PNU-120596, TQS), and intermediate type-I/II PAMs
(JNJ-39393406, AF58801) resulted in concentration-dependent in-
creases in intracellular calcium, which could be concentration-depen-
dently inhibited by MLA (Fig. 3A).
3.4. Synchronized calcium oscillations in hiPSC-derived neural networks
are orchestrated by NMDA and ACh receptors
To assess whether hiPSC-derived neurons could serve as a synaptic
transmission model, neural cultures were matured for ﬁve weeks. At
this point, they contained 96±3% TUJ1 positive neurons and a small
population of GFAP positive glia cells 4 ± 3% (n=3, m=110–306,
example of image shown in Fig. 4A). The cultures consistently exhibited
spontaneous calcium oscillations as described above. Furthermore, they
contained chemical synapses signiﬁed by positive stains for the pre-
synaptic markers synapsin-1 and vesicular glutamate transporter
(Fig. 4A).
Gene expression proﬁles of selected NMDA, AMPA and GABA re-
ceptor subunits showed upregulation of all subunits in hiPSC-derived
neurons versus undiﬀerentiated hiPSCs using qPCR (Fig. 4B). The data
are in line with the functional neurotransmitter responses (Fig. 1D)
supporting the presence of GABA, acetylcholine, and glutamate re-
ceptors. NMDA receptors are composed of two NR1 and two NR2
subunits, which can be either subtype A, B, C or D. The strongest in-
crease in NR2 subunit expression was observed for the NR2B subunit
(GRIN2B, Fig. 4B). We applied four NMDA antagonists with partial
selectivity for diﬀerent NMDA receptor subunits to further investigate
the subunit identity (Fig 4E). The NR2A/B antagonist ketamine (10 μM)
as well as the NR2B antagonists TCN237 (10 μM) and ifenprodil
(10 μM) reduced the calcium oscillation frequency, while the NR2C/D
antagonist QNZ46 (10 μM) showed no eﬀect. Collectively, gene ex-
pression and calcium oscillation data indicate that a majority of the
NMDA receptor complexes are composed of NR2B.
We investigated the eﬀects of NMDA, AMPA, GABA and acet-
ylcholine receptor antagonists or modulators on the frequency and
amplitude of the calcium oscillation in the neurons. It should be noted
that due to the binding dynamics of the calcium sensitive probe, the two
parameters are not completely independent. The NMDA receptor an-
tagonist MK-801 (50 μM) abolished all calcium oscillations (Fig. 4D).
Bicuculline (100 μM), a GABAA receptor antagonist, signiﬁcantly re-
duced the peak frequency (0.6 ± 0.03 fold, P<0.05, Fig. 4D). The α7
antagonist mecamylamine (10 μM) signiﬁcantly reduced peak fre-
quency (0.7 ± 0.1 fold, P<0.01, Fig. 4D). Application of diazepam
(Fig. 4C), a GABAA receptor PAM, showed an increase in frequency
(1.7 ± 0.3 fold, P<0.05) and a decrease in amplitude (0.4 ± 0.1,
P<0.005). The observed eﬀects of modulating GABA are in line with
the observation that GABA is excitatory in the present model (see
Section 3.1). The AMPA PAM Cx516 (Fig. 4E) had no signiﬁcant eﬀects
on the tested parameters, although AMPA subunit 1 was upregulated
(GRIA, day 28, 114±10 fold). This does not exclude the presence of
AMPA receptors, but indicate that they do not modulate the calcium
oscillations. Overall, the data show NMDA NR2B complex mediated
synchronized calcium oscillations and modulation of the synaptic
transmission by GABA and acetylcholine receptors.
The α7 receptor has previously been reported to modulate synaptic
transmission and ease the threshold for glutamate release in hippo-
campus and pre-frontal cortex (Alkondon et al., 2000; Alkondon and
Albuquerque, 2001; Cheng and Yakel, 2014; Gray et al., 1996;
Fig. 4. hiPSC neural networks show NMDA-mediated synchronized calcium oscillations that are modulated by α7 and GABA receptors.
A: Immunocytochemistry of astrocyte marker GFAP, glutamate transporter vGLUT, post-mitotic neuron marker NEUN, and synapse marker synapsin. βIII-tubulin
(TuJ1) was used to indicate neurites. Scale bars: 100 μm (d21, n=3, m=1, BIONi010A shown). B: qPCR for gene expression of GABA (GABRA1, P<0.001 day 21
and P<0.0001 day 35 compared to day 0), AMPA (GRIA1, P<0.01 day 14 and P<0.0001 day 28–35 compared to day 0) and NMDA subunits (GRIN1, P<0.001 day
21 and P<0.0001 day 28–35 compared to day 0. GRIN2A, P<0.01 day 21, P<0.001 day 28 and P<0.0001 day 35 compared to day 0. GRIN2B, P<0.001 day 21 and
P<0.0001 day 28–35 compared to day 0. GRIN2C, P<0.05 day 28. GRIN2D, P<0.05 day 14, P<0.001 day 21+35 and P<0.0001 day 28 compared to day 0) at
diﬀerent stages of neuronal diﬀerentiation (mean± SEM, n=3, m=4). C/D/E/F: Change in intracellular calcium oscillations following treatment with C) 10 μM
NR2C/NR2D antagonist QNZ46 (QNZ), 10 μM NR2A/NR2B antagonist ketamine (Keta), 10 μM NR2B antagonist TCN237 (TCN), and 10 μM NR2B antagonist
ifenprodil (ifen). The vertical black line indicates compound application. D) 10 μM ACh antagonist mecamylamine (Mec), 100 μM GABA antagonist bicuculline
(Bicu), and 50 μM NMDA antagonist MK-801, E) 1 μM GABA PAM diazepam (Diaze), and 250 μM AMPA PAM Cx516, F) 10 μM α7 PAM PNU-120596 and 1 μM α7
antagonist MLA, Traces are representative. Data are depicted as mean±SEM (d36-39, n=3–6, m=4–6). All ﬁgure panels: Statistical signiﬁcance was determined
using ordinary ANOVA followed by post hoc Dunnett's multiple comparison test; *P<0.05, **P<0.01, ***P<0.005.
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Sharma et al., 2008). To test the α7 receptors’ eﬀect on calcium oscil-
lations in our neuronal network model, we applied PNU-120596
(10 μM) or MLA (1 μM). PNU-120596 resulted in a signiﬁcant increase
in oscillation frequency (1.6 ± 0.2 fold, P<0.05), while MLA had no
eﬀect (Fig. 4F). Hence, a positive modulation of α7 intensiﬁed the os-
cillation frequency, while α7 receptor inhibition did not aﬀect the
calcium oscillation parameters. This demonstrates the involvement of
the α7 receptor in synaptic transmission in the hiPSC neurons.
4. Discussion
Given the interest in the α7 receptor as a target for treatment of
cognitive impairment in neurological disease such as Alzheimer's dis-
ease and schizophrenia, we used our previously established hiPSC
neural culture (Hansen et al., 2016) to study endogenously expressed
α7 receptors. Our model system has a good throughput as one 6-well of
hiPSCs generates 1200–1600 96-well plates (50.000 cells/well) of
neurons(present study and Hansen et al., 2016). The neuronal diﬀer-
entiations of the NSCs were highly reproducible. The hiPSC-derived
neurons exhibited neuronal identity as they expressed mRNA and
protein for neuronal markers, responded to membrane depolar-
ization,demonstrated expression of functional neurotransmitter re-
ceptorsand had synaptic connections and spontaneous calcium oscilla-
tions. Hence, the scalability, reproducibility and cellular identity of the
model qualiﬁes it for use in pharmaceutical research.
We demonstrated the expression of several diﬀerent nAChR subunit
transcripts in the neuronal cultures indicating the presence of a het-
erogeneous population of nAChRs. This was functionally conﬁrmed by
the pharmacological characterization in the intracellular calcium assay.
Potentiation of acetylcholine, nicotine and PNU-282987 by α7 receptor
PAM PNU-120596 and inhibition of this potentiation with the α7 an-
tagonist MLA demonstrated the presence of functional α7 receptors.
This was substantiated by the presence of concentration-dependent
responses to the α7 receptor agonist PNU-282987 in combination with
either of four α7 receptor type-I/II or type II PAMs. Moreover, we
showed that α7 activation stimulated intracellular signaling in the form
of increased c-Fos expression and phosphorylation of ERK 1/2. In line
with other α7 receptor studies in mammalian cells, we saw no or very
minor eﬀect of agonist alone on intracellular calcium levels, ERK 1/2
phosphorylation and c-Fos expression. This is probably due to the rapid
desensitization of α7 nAChR that is induced by orthosteric agonists. Our
data also showed that the α7 induced increases in intracellular calcium
levels were partly due to inﬂux via the α7 receptor itself, and partly due
to calcium inﬂux via voltage-gated calcium channels and release from
intracellular stores. This is in line with ﬁndings in PC12 (Guerra-
Álvarez et al., 2015) and SH-SY5Y cells (Dajas-Bailador et al., 2002a).
The fact that the voltage-gated sodium channel inhibitor TTX diminish
the signal could points to either reduced opening of voltage-gated cal-
cium channels or reduced axonal signal transmission limiting activation
of other subpopulation of neurons not expressing α7 nAChRs. Overall,
the α7 receptors in the hiPSC-derived neurons showed the expected
pharmacological activation patterns and biologically relevant in-
tracellular signaling and interactions.
Interestingly, the gene expression of TMEM35 was up-regulated
during neural maturation and the TMEM35 protein levels in hiPSC-
derived neuronal cultures corresponded to levels in PC12 cells. A study
has demonstrated TMEM35 to be transiently expressed in the pre-
frontal cortex of postnatal rats, and that activation of α7 increased
TMEM35 protein levels (Wichern et al., 2017). This pattern of co-ex-
pression is in agreement with another publication showing TMEM35 to
be required for surface localization of α7 and the hetero-pentameric
α4β2 nAChRs (Gu et al., 2016). In our study, gene expression levels of
TMEM35 also correlated with expression of CHRNA7, CHRNA4, and
CHRNB2 mRNA. Consequently, our hiPSC-derived neuronal model is a
valid candidate for investigations of TMEM35 and the traﬃcking dy-
namics of α7 and other nAChR subunits.
Primary cortical neurons and neurons derived from human em-
bryonic stem cells possess synchronized spontaneous calcium oscilla-
tions (Dravid and Murray, 2004; Kiiski et al., 2013). We were among
the ﬁrst to demonstrate synchronized spontaneous calcium oscillations
in hiPSC neurons (Hansen et al., 2016; Kirwan et al., 2015). In the
current study, we characterize the synaptic transmission driving the
network activity. During early embryonic development gap junctions
mediate neuronal network activity, while chemical synaptic transmis-
sion takes over later in prenatal development (Blankenship and
Feller, 2010; Sutor and Hagerty, 2005). Expression of synapsin-1 and
vesicular glutamate transporter protein in our neuronal cultures
pointed to the presence of chemical synapsis. The eﬀects of NMDA,
GABA and acetylcholine receptor antagonists and AMPA and GABA
PAMs on the calcium network activity proved roles for NMDA, GABA,
and acetylcholine, but not AMDA, neurotransmitters in basal synaptic
transmission. In line, we showed gene expression upregulation of the
corresponding receptor subunits, and we have previously demonstrated
upregulations of the neurotransmitter synthesis rate limiting enzymes,
choline acetyltransferase and glutamate decarboxylase 1 (Hansen et al.,
2016). Gene expression data in the present study indicated that the
larger proportion of the NMDA receptor complexes are composed of
NR2B, which may point to a more embryonic NMDA subunit compo-
sition (Ewald and Cline, 2009; Zhang and Sun, 2011). Overall, we de-
monstrate a hiPSC-derived neural network of a relatively advanced
neuronal maturity where NMDA, GABA, and acetylcholine signaling
mediated synaptic transmission. Our ﬁndings add important knowledge
to earlier publication on hiPSC-derived neurons investigating ex-
clusively glutamatergic modulation (Kirwan et al., 2015).
Several studies have shown that presynaptic a7 receptors can
modulate GABAergic (Alkondon et al., 2000; Alkondon and
Albuquerque, 2001) and glutamatergic synaptic transmission in murine
hippocampus (Alkondon et al., 2000; Alkondon and
Albuquerque, 2001; Gray et al., 1996). Importantly, our human model
conﬁrmed involvement of the α7 receptor in synaptic transmission. We
show that application of α7 receptor PAM PNU-120596 caused a strong
increase in calcium oscillation peak frequency. In contrast to the gen-
eral nicotinic acetylcholine receptor antagonist mecamylamine, the α7
antagonist MLA had no eﬀects on the oscillation parameters, implying
that acetylcholine signaling through the α7 receptor has no prominent
eﬀect on basal synaptic activity but rather plays a prominent role for
increasing synaptic activity. This opens potential for use of the network
activity assay in α7 drug discovery, especially as the ﬂuorescent probe-
based assay provides higher throughput than traditional assessments of
neuronal network activity (e.g. multi electrode recordings).
5. Conclusions
We have successfully demonstrated that hiPSC can be used to gen-
erate a reproducible model system with a throughput that enables its
use in pharmacological screening. The neurons could consistently be
matured into cultures exhibiting synchronized spontaneous calcium
oscillations which were facilitated by NMDA, GABA, and acetylcholine
receptors. We clearly demonstrate the presence of functional α7 re-
ceptors as early as the second week of neural maturation and showed
eﬀect of several type I/II and type II α7 PAMs. We substantiate that our
hiPSC-based model is a useful tool for studying pharmacology of en-
dogenously expressed native α7 receptors with relevant cellular func-
tions, as well as for studying receptors implicated in synaptic trans-
mission. Importantly, we demonstrate a role for α7 receptors role in
increasing synaptic transmission. We anticipate that such approaches
could potentially be used as a phenotypic endpoint in patient-speciﬁc
hiPSC-based investigations of Alzheimer's disease or schizophrenia.
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